High-risk cardiovascular patients: Clinical features, comorbidities, and interconnecting mechanisms

Frontiers in Immunology

Volumn 6, Issue NOV, 2015, Pages

  Schuett, Katharina Andrea ^a   Lehrke, Michael ^a   Marx, Nikolaus ^a   Burgmaier, Mathias ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Atherosclerosis; Cardiovascular disease; Coagulation; Inflammation; Rheumatoid arthritis; Systemic lupus erythematosus; Type 2 diabetes mellitus

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; CD40 ANTIGEN; CD40 LIGAND; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MANNOSE BINDING LECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NITRIC OXIDE; PHOSPHATIDYLSERINE; RANTES; THROMBIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIABETES MELLITUS; ENDOTHELIUM CELL; EXTRACELLULAR TRAP; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MEMBRANE MICROPARTICLE; META ANALYSIS (TOPIC); NEUTROPHIL; NONHUMAN; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE FUNCTION;

EID: 84949552927     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00591     Document Type: Review

References (112)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 339:229-34. doi: 10.1056/NEJM199807233390404.
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 287:2570-81. doi:10.1001/jama.287.19.2570.
3. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 113:e85-151. doi:10.1161/CIRCULATIONAHA.105.171600.
4. Rugg SS, Bailey AL, Browning SR. Preventing cardiovascular disease in Kentucky: epidemiology, trends, and strategies for the future. J Ky Med Assoc (2008) 106:149-61; quiz 149, 162-3.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation (2002) 105:1135-43. doi:10.1161/hc0902.104353.
6. Falk E, Fernandez-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol (1995) 75:3B-11B. doi:10.1016/0002-9149(95)80003-B.
7. Libby P. Inflammation in atherosclerosis. Nature (2002) 420:868-74. doi:10.1038/nature01323.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 352:1685-95. doi:10.1056/NEJMra043430.
9. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res (2015) 116:307-11. doi:10.1161/CIRCRESAHA.116.301313.
10. Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol (2009) 20:370-8. doi:10.1097/MOL.0b013e3283309848.
11. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 8:802-15. doi:10.1038/nri2415.
12. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity (2013) 38:1092-104. doi:10.1016/j.immuni.2013.06.009.
13. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med (2008) 263:489-99. doi:10.1111/j.1365-2796.2008.01944.x.
14. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation (1999) 99:237-42.
15. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 359:2195-207. doi:10.1056/NEJMoa0807646.
16. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med (2010) 38:S26-34. doi:10.1097/CCM.0b013e3181c98d21.
17. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2003) 52:1799-805. doi:10.2337/diabetes.52.7.1799.
18. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res (2005) 96:939-49. doi:10.1161/01.RES.0000163635.62927.34.
19. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol (2005) 25:2062-8. doi:10.1161/01.ATV.0000183883.72263.13.
20. Walport MJ. Complement. First of two parts. N Engl J Med (2001) 344:1058-66. doi:10.1056/NEJM200104053441406.
21. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 11:785-97. doi:10.1038/ni.1923.
22. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J (2010) 74:597-607. doi:10.1253/circj. CJ-09-0982.
23. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev (2003) 8:71-86. doi:10.1023/A:1022199021949.
24. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol (2011) 11:264-74. doi:10.1038/nri2956.
25. Zhang W, Huang W, Jing F. Contribution of blood platelets to vascular pathology in Alzheimer's disease. J Blood Med (2013) 4:141-7. doi:10.2147/JBM.S45071.
26. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation (2002) 106:896-9. doi:10.1161/01.CIR.0000028962.04520.01.
27. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol (2010) 47:2170-5. doi:10.1016/j.molimm.2010.05.009.
28. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, NeffTA, Mcguire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 12:682-7. doi:10.1038/nm1419.
29. Cosgrove LJ, D'Apice AJ, Haddad A, Pedersen J, Mckenzie IF. CR3 receptor on platelets and its role in the prostaglandin metabolic pathway. Immunol Cell Biol (1987) 65:453-60. doi:10.1038/icb.1987.54.
30. Nunez D, Charriaut-Marlangue C, Barel M, Benveniste J, Frade R. Activation of human platelets through gp140, the C3d/EBV receptor (CR2). Eur J Immunol (1987) 17:515-20. doi:10.1002/eji.1830170413.
31. La Bonte LR, Pavlov VI, Tan YS, Takahashi K, Takahashi M, Banda NK, et al. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol (2012) 188:885-91. doi:10.4049/jimmunol.1102916.
32. Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-arg. J Exp Med (1983) 158:603-15. doi:10.1084/jem.158.2.603.
33. Martel C, Cointe S, Maurice P, Matar S, Ghitescu M, Théroux P, et al. Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS One (2011) 6:e18812. doi:10.1371/journal.pone.0018812.
34. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med (2005) 201:871-9. doi:10.1084/jem.20041497.
35. Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost (2013) 110:910-9. doi:10.1160/TH13-02-0102.
36. Mnjoyan Z, Li J, Afshar-Kharghan V. Factor H binds to platelet integrin alphaIIbbeta3. Platelets (2008) 19:512-9. doi:10.1080/09537100802238494.
37. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res (2010) 7:260-73. doi:10.1177/1479164110383723.
38. Breitenstein A, Tanner FC, Lüscher TF. Tissue factor and cardiovascular disease. Circ J (2010) 74:3-12. doi:10.1253/circj. CJ-09-0818.
39. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood (1997) 89:541-9.
40. Steffel J, Hermann M, Greutert H, Gay S, Lüscher TF, Ruschitzka F, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation (2005) 111:1685-9. doi:10.1161/01.CIR.0000160358.63804.C9.
41. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation (2006) 113:722-31. doi:10.1161/CIRCULATIONAHA.105.567297.
42. Gulla KC, Gupta K, Krarup A, Gal P, Schwaeble WJ, Sim RB, et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology (2010) 129:482-95. doi:10.1111/j.1365-2567.2009.03200.x.
43. Hess K, Ajjan R, Phoenix F, Dobó J, Gál P, Schroeder V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS One (2012) 7:e35690. doi:10.1371/journal.pone.0035690.
44. Krarup A, Wallis R, Presanis JS, Gál P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One (2007) 2:e623. doi:10.1371/journal.pone.0000623.
45. Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood (1995) 85:1517-26.
46. Distelmaier K, Adlbrecht C, Jakowitsch J, Winkler S, Dunkler D, Gerner C, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost (2009) 102:564-72. doi:10.1160/TH09-02-0103.
47. Hess K, Alzahrani S, Mathai M, Schroeder V, Carter AM, Howell G, et al. A novel mechanism for hypofibrinolysis in diabetes: the role of Complement C3. Diabetologia (2012) 55:1103-13. doi:10.1007/s00125-011-2301-7.
48. Howes JM, Richardson VR, Smith KA, Schroeder V, Somani R, Shore A, et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res (2012) 9:216-25. doi:10.1177/1479164111432788.
49. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 177:4794-802. doi:10.4049/jimmunol.177.7.4794.
50. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 28:184-92. doi:10.1016/j.it.2007.02.006.
51. Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR. Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol (1999) 36:261-8. doi:10.1016/S0161-5890(99)90054-8.
52. Zafrani L, Gerotziafas G, Byrnes C, Hu X, Perez J, Lévi C, et al. Calpastatin controls polymicrobial sepsis by limiting procoagulant microparticle release. Am J Respir Crit Care Med (2012) 185:744-55. doi:10.1164/rccm.201109-1686OC.
53. Feng B, Chen Y, Luo Y, Chen M, Li X, Ni Y. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis (2010) 208:264-9. doi:10.1016/j.atherosclerosis.2009.06.037.
54. Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol (2010) 26:140-5. doi:10.1016/S0828-282X(10)70371-8.
55. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest (2004) 34:392-401. doi:10.1111/j.1365-2362.2004.01355.x.
56. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA (2004) 10:1957-66. doi:10.1261/rna.7135204.
57. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 20:847-56. doi:10.1038/sj.leu.2404132.
58. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood (2011) 118:1952-61. doi:10.1182/blood-2011-03-343061.
59. Bosmann M, Grailer JJ, Ruemmler R, Russkamp NF, Zetoune FS, Sarma JV, et al. Extracellular histones are essential effectors of C5aR-and C5L2-mediated tissue damage and inflammation in acute lung injury. FASEB J (2013) 27:5010-21. doi:10.1096/fj.13-236380.
60. Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki S, et al. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J (2015) 36(22):1405-14. doi:10.1093/eurheartj/ehv007.
61. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med (1999) 340:115-26. doi:10.1056/NEJM199901143400207.
62. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 30:1066-72. doi:10.1093/eurheartj/ehp049.
63. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb (2010) 17:1-11. doi:10.5551/jat.2600.
64. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J (2010) 160:583-94. doi:10.1016/j.ahj.2010.06.010.
65. Turkyilmaz AK, Devrimsel G, Kirbas A, Cicek Y, Karkucak M, Capkin E, et al. Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis. Rheumatol Int (2013) 33:2751-6. doi:10.1007/s00296-013-2810-4.
66. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation (2014) 130:837-44. doi:10.1161/CIRCULATIONAHA.114.009990.
67. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2005) 52:402-11. doi:10.1002/art.20878.
68. Wang S, Yiu KH, Mok MY, Ooi GC, Khong PL, Mak KF, et al. Prevalence and extent of calcification over aorta, coronary and carotid arteries in patients with rheumatoid arthritis. J Intern Med (2009) 266:445-52. doi:10.1111/j.1365-2796.2009.02123.x.
69. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol (2009) 29:1702-8. doi:10.1161/ATVBAHA.109.190108.
70. Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol (2007) 34:937-42.
71. Karpouzas GA, Malpeso J, Choi TY, Li D, Munoz S, BudoffMJ. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis (2014) 73:1797-804. doi:10.1136/annrheumdis-2013-203617.
72. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol (2015) 11(7):390-400. doi:10.1038/nrrheum.2015.40.
73. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 44:2737-45. doi:10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#.
74. Arts EE, Popa C, Den Broeder AA, Semb AG, Toms T, Kitas GD, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis (2015) 74:668-74. doi:10.1136/annrheumdis-2013-204024.
75. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J (2015) 36:482c-9c. doi:10.1093/eurheartj/ehu403.
76. Cahill GF Jr. C-peptide: a new method of assessing pancreatic beta-cell function. N Engl J Med (1973) 288:1181-2. doi:10.1056/NEJM197305312882210.
77. Burgmaier M, Hoppe S, Kruger T, Mahnken AH, Ketteler M, Reith S, et al. Serum levels of C-peptide are associated with coronary artery calcification in patients with rheumatoid arthritis. Rheumatol Int (2015) 35(9):1541-7. doi:10.1007/s00296-015-3244-y.
78. Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int (2001) 20:192-6. doi:10.1007/s002960100115.
79. Zheng JL, Lu L, Hu J, Zhang RY, Zhang Q, Chen QJ, et al. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis (2010) 210:590-5. doi:10.1016/j.atherosclerosis.2009.12.016.
80. Bakker MF, Cavet G, Jacobs JW, Bijlsma JW, Haney DJ, Shen Y, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis (2012) 71:1692-7. doi:10.1136/annrheumdis-2011-200963.
81. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol (1995) 22:1259-64.
82. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol (1995) 22:1265-70.
83. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med (1976) 60:221-5. doi:10.1016/0002-9343(76)90431-9.
84. Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus (2007) 16:309-17. doi:10.1177/0961203307077987.
85. Lin CY, Shih CC, Yeh CC, Chou WH, Chen TL, Liao CC. Increased risk of acute myocardial infarction and mortality in patients with systemic lupus erythematosus: two nationwide retrospective cohort studies. Int J Cardiol (2014) 176:847-51. doi:10.1016/j.ijcard.2014.08.006.
86. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) (1992) 71:291-302. doi:10.1097/00005792-199209000-00004.
87. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, Du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 44:2331-7. doi:10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I.
88. Ballocca F, D'Ascenzo F, Moretti C, Omede P, Cerrato E, Barbero U, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol (2015) 22(11):1435-41. doi:10.1177/2047487314546826.
89. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum (2006) 54:3918-25. doi:10.1002/art.22265.
90. Bartoloni Bocci E, Luccioli F, Angrisani C, Moscatelli S, Alunno A, Gerli R. Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases. Expert Rev Clin Immunol (2007) 3:531-41. doi:10.1586/1744666X.3.4.531.
91. Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med (2013) 64:249-63. doi:10.1146/annurev-med-060911-090007.
92. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab (2010) 5:19-28. doi:10.1586/eem.09.44.
93. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev (2007) 65:S253-9. doi:10.1111/j.1753-4887.2007.tb00372.x.
94. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab (2009) 94:3171-82. doi:10.1210/jc.2008-2534.
95. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome-an allostatic perspective. Biochim Biophys Acta (2010) 1801:338-49. doi:10.1016/j.bbalip.2009.12.006.
96. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol (2011) 29:415-45. doi:10.1146/annurev-immunol-031210-101322.
97. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology (2007) 132:2169-80. doi:10.1053/j.gastro.2007.03.059.
98. Huang S, Rutkowsky JM, Snodgrass RG, Ono-Moore KD, Schneider DA, Newman JW, et al. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res (2012) 53:2002-13. doi:10.1194/jlr. D029546.
99. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 11:183-90. doi:10.1038/nm1166.
100. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med (2010) 152:346-57. doi:10.7326/0003-4819-152-6-201003160-00004.
101. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med (2007) 356:1517-26. doi:10.1056/NEJMoa065213.
102. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 162:597-605. doi:10.1016/j.ahj.2011.06.012.
103. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J (2013) 166(199-207):e115. doi:10.1016/j.ahj.2013.03.018.
104. Serino M, Luche E, Chabo C, Amar J, Burcelin R. Intestinal microflora and metabolic diseases. Diabetes Metab (2009) 35:262-72. doi:10.1016/j.diabet.2009.03.003.
105. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care (2011) 34:392-7. doi:10.2337/dc10-1676.
106. Laugerette F, Vors C, Peretti N, Michalski MC. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie (2011) 93:39-45. doi:10.1016/j.biochi.2010.04.016.
107. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A (2004) 101:10679-84. doi:10.1073/pnas.0403249101.
108. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes (2007) 56:1986-98. doi:10.2337/db06-1595.
109. Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) (2008) 16:1248-55. doi:10.1038/oby.2008.210.
110. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 56:1761-72. doi:10.2337/db06-1491.
111. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes (2008) 57:1470-81. doi:10.2337/db07-1403.
112. Rabot S, Membrez M, Bruneau A, Gerard P, Harach T, Moser M, et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J (2010) 24:4948-59. doi:10.1096/fj.10-164921.